DV
Dividend Vision

TRVI — Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (TRVI)

Total return is 134.0% over the past 7.3 years, 66.1 points behind SPY at 200.1%. Its deepest 1-year drawdown was 29.5%.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing investigational therapies for chronic cough, primarily its lead candidate Haduvio (an oral nalbuphine formulation) which is in phase 2b trials for patients with idiopathic pulmonary fibrosis and phase 2a trials for refractory chronic cough. As a pre-revenue clinical-stage biotech company, it does not currently distribute income. This company appeals to investors with high risk tolerance seeking exposure to early-stage pharmaceutical development rather than those focused on income generation.

TRVI key facts

Asset type
Stock
Asset class
Equity
Inception date
05/07/2019
Distribution frequency
None
Last close
$18.46
Market cap
$2,630,103,808
Average volume
1389700.0
Beta
1.072
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.35